Irvine, CA (PRWEB) May 04, 2016 -- Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is excited to announce a strategic partnership with McGill University. The partnership is designed to advance research in pain genetics in an effort to bring new discoveries to the market in order to help patients in pain. With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda Diatechnko, MD, PhD. Dr. Diatchenko is a professor at McGill University’s Alan Edwards Centre for Research on Pain and is the Canada Excellence Research Chair in Human Pain Genetics. As a leading authority in the field, Dr. Diatchenko evaluates the molecular, cellular, and genetic pathways involved in pain.
“We are excited to work with one of the world’s leading researchers in pain genetics,” said Brian Meshkin. “As Dr. Diatchenko makes new discoveries regarding the link between genetics and pain perception, we are able to share insights about how our technology is able to compute massive amounts of data to help individual patients.” Currently, Proove Biosciences uses a proprietary technology platform to assess the role genetics plays in pain perception. With the Proove Pain Perception® profile, for example, the company is able to quantify patient pain based on genetic variations and related health information. “By working together, we are able to take our research findings and create real-world applications for patients in pain,” said Diatchenko.
As part of this agreement, McGill University and Proove Biosciences are expected to work collaboratively to inform the scientific community on new discoveries and potential therapeutic applications for pain patients. As a strategic partner, Proove Biosciences is committed to taking research from the lab and offering solutions for people in Canada and the Untied States. “We’re facing a global epidemic in which patients are putting themselves at risk to address chronic pain,” explained Meshkin. “Often, this leads to the misuse of pain medication—and that opens the door to addiction.” The researchers at Proove Biosciences use products that assess patients for risk to addiction along with pain perception to help doctors make more informed decisions. “Everything starts with pain,” said Meshkin. “If we can work with our strategic partners to quantify pain and identify high risk patients, we are able to give doctors the tools they need to address pain on an individual level.”
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes—both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Proove Public Relations, Proove Biosciences, http://www.proove.com, +1 949-556-7239, [email protected]